Amedisys Revenue Charts (NASDAQ:AMED)
$49.34 $0.22 (0.45%) AMED stock closing price Aug 15, 2017 (Closing)
The latest 2017-Q2 Amedisys revenue is 378.82M. Compare Amedisys revenue chart with Chemed revenue, Surgical Care Affiliates revenue.
Amedisys Revenue Chart
You can do annual as well as quarterly comparisons of Amedisys Inc net sales with its competitor companies like Chemed, Surgical Care Affiliates. Over the 5 year period Amedisys revenue in 2012 was highest at 1.49B. In the latest quarter, AMED revenue 2017-Q2 has changed from 370.46M to 378.82M implying an increase of 2.26%.
Amedisys Quarterly Revenue
* Past 5 years Range
|Max AMED Revenue||$378.82M||Jun, 2017|
|Min AMED Revenue||$298.74M||Mar, 2014|
Amedisys Annual Revenue
* Past 5 years Range
|Max AMED Revenue||$1.49B||Dec, 2012|
|Min AMED Revenue||$1.2B||Dec, 2014|
Amedisys Annual Revenue VS Peers
|Surgical Care Affiliates Revenue||$1.28B||$1.05B||$864.73M||$802.03M||$744.86M|
|Almost Family Revenue||$623.54M||$532.21M||$495.82M||$357.81M||$348.52M|
|Gentiva Health Services Revenue||----||----||----||$1.73B||$1.71B|
Amedisys Stock Articles
Buy Exxon Mobil Stock, eBay Inc Stock And Sell Vascular Biogenics Stock- Today's Top RSI Stock Trades
Revenue or net sales is the total amount of money that a company brings in through its various business activities. Revenue is also known as the top line or net sales or gross income. Revenue is for a specific period of time and appears as the "top line" in an income statement. By subtracting the costs or expenses from Amedisys topline we arrive at the bottom line for the company. Increasing revenues over a period of time is generally a sign of a healthy company, however other factors need to be taken into consideration. Revenue can be calculated in two ways based on the type of accounting followed: accrual accounting or cashflow accounting. It helps to compare Amedisys revenue with peers Chemed topline, Surgical Care Affiliates topline, Almost Family topline; to see how the company is doing with respect to its peers.